Report Detail

Medical Devices & Consumables Global Common Cancer-associated Antigens (CAAs) Vaccine Market Status and Forecast 2021-2027

  • RnM4332582
  • |
  • 19 July, 2021
  • |
  • Global
  • |
  • 139 Pages
  • |
  • GRD Survey
  • |
  • Medical Devices & Consumables

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Status and Forecast (2016-2027)
      • 1.3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Common Cancer-associated Antigens (CAAs) Vaccine Supply by Company

    • 2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Company
    • 2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Company
    • 2.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Price by Company
    • 2.4 Common Cancer-associated Antigens (CAAs) Vaccine Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Common Cancer-associated Antigens (CAAs) Vaccine Market Status by Type

    • 3.1 Common Cancer-associated Antigens (CAAs) Vaccine Type Introduction
      • 3.1.1 Tecemotide
      • 3.1.2 Astuprotimut-R
      • 3.1.3 Tertomotide
      • 3.1.4 Nelipepimut-S
      • 3.1.5 Others
    • 3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market by Type
      • 3.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Type (2016-2021)
      • 3.2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Type (2016-2021)
      • 3.2.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Price by Type (2016-2021)
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Common Cancer-associated Antigens (CAAs) Vaccine Market Status by Application

    • 4.1 Common Cancer-associated Antigens (CAAs) Vaccine Segment by Application
      • 4.1.1 Pediatrics
      • 4.1.2 Adults
    • 4.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market by Application
      • 4.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Application (2016-2021)
      • 4.2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Application (2016-2021)
      • 4.2.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Price by Application (2016-2021)
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Status by Region

    • 5.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market by Region
      • 5.1.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Region
      • 5.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Region
    • 5.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Status
    • 5.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Status
    • 5.4 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Status
    • 5.5 Central & South America Common Cancer-associated Antigens (CAAs) Vaccine Market Status
    • 5.6 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Status

    6 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Status

    • 6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market by Country
      • 6.1.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Country (2016-2021)
      • 6.1.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Status

    • 7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market by Country
      • 7.1.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Status

    • 8.1 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market by Country
      • 8.1.1 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Common Cancer-associated Antigens (CAAs) Vaccine Market Status

    • 9.1 Central & South America Common Cancer-associated Antigens (CAAs) Vaccine Market by Country
      • 9.1.1 Central & South America Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Status

    • 10.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market by Country
      • 10.1.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Common Cancer-associated Antigens (CAAs) Vaccine Manufacturing Cost Analysis
    • 11.5 Common Cancer-associated Antigens (CAAs) Vaccine Sales Channel and Distributors Analysis
      • 11.5.1 Common Cancer-associated Antigens (CAAs) Vaccine Sales Channel
      • 11.5.2 Common Cancer-associated Antigens (CAAs) Vaccine Distributors
    • 11.6 Common Cancer-associated Antigens (CAAs) Vaccine Downstream Major Buyers

    12 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Forecast by Type and by Application

    • 12.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecast by Type
      • 12.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume Forecast by Type
      • 12.2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value Forecast by Type
      • 12.2.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Price Forecast by Type
    • 12.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecast by Application
      • 12.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume Forecast by Application
      • 12.3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value Forecast by Application
      • 12.3.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Price Forecast by Application

    13 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Forecast by Region/Country

    • 13.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Forecast by Region (2022-2027)
      • 13.1.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 SELLAS Life Sciences
      • 14.1.1 Company Information
      • 14.1.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.1.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Seattle Genetics
      • 14.2.1 Company Information
      • 14.2.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.2.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Merck Serono
      • 14.3.1 Company Information
      • 14.3.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.3.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Merck KGaA
      • 14.4.1 Company Information
      • 14.4.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.4.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 KAEL-GemVax
      • 14.5.1 Company Information
      • 14.5.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Immatics Biotechnologies
      • 14.6.1 Company Information
      • 14.6.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.6.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 GlaxoSmithKline
      • 14.7.1 Company Information
      • 14.7.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.7.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Celldex
      • 14.8.1 Company Information
      • 14.8.2 Common Cancer-associated Antigens (CAAs) Vaccine Product Introduction
      • 14.8.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      This report provides a comprehensive analysis of current global Common Cancer-associated Antigens (CAAs) Vaccine market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario. This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Common Cancer-associated Antigens (CAAs) Vaccine industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

      According to this survey, the global Common Cancer-associated Antigens (CAAs) Vaccine market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

      Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Common Cancer-associated Antigens (CAAs) Vaccine market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

      The Global Common Cancer-associated Antigens (CAAs) Vaccine Market has been exhibited in detail in the following chapters
      Chapter 1 displays the basic product introduction and market overview.
      Chapter 2 provides the competition landscape of global Common Cancer-associated Antigens (CAAs) Vaccine industry.
      Chapter 3 provides the market analysis by type and by region
      Chapter 4 provides the market analysis by application and by region
      Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
      Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
      Chapter 12 provides the market forecast by type and by application
      Chapter 13 provides the market forecast by region
      Chapter 14 profiles global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
      Chapter 15 conclusions

      Segmented by Type
      Tecemotide
      Astuprotimut-R

      Segmented by Application
      Pediatrics
      Adults

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Merck Serono
      Merck KGaA
      KAEL-GemVax
      Immatics Biotechnologies
      GlaxoSmithKline
      Celldex


      Summary:
      Get latest Market Research Reports on Common Cancer-associated Antigens (CAAs) Vaccine. Industry analysis & Market Report on Common Cancer-associated Antigens (CAAs) Vaccine is a syndicated market report, published as Global Common Cancer-associated Antigens (CAAs) Vaccine Market Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Common Cancer-associated Antigens (CAAs) Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,980.00
      $4,470.00
      $5,960.00
      2,139.64
      3,209.46
      4,279.28
      2,512.14
      3,768.21
      5,024.28
      325,684.20
      488,526.30
      651,368.40
      221,056.40
      331,584.60
      442,112.80
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report